PCN12 COLORECTAL CANCER: COST-EFFECTIVENESS OF SCREENING AND CHEMOPREVENTION IN AVERAGE RISK MALES  by Coffindaffer, JW et al.
A126 Abstracts
neutropenia (FN) in chemotherapy regimens with a high risk of
FN, pegﬁlgrastim was recently shown to decrease the relative risk
of FN by 0.94 in regimens with a moderate risk (<20%). We esti-
mated the cost-effectiveness ($ per FN episode avoided, $/life
year gained [LYG]) of pegﬁlgrastim primary (starting in cycle 1)
vs. secondary (after FN) prophylaxis in women with early-stage
breast cancer receiving chemotherapy with a moderate risk of
FN. METHODS: We created a decision-analytic model from a
payor’s perspective. The base case considers costs and outcomes
related to reduced FN. Secondary analyses considered potential
survival beneﬁts due to reduced FN-related mortality, and
cancer-speciﬁc long-term survival gains due to increased
chemotherapy dose intensity. Costs included drug costs, FN-
related hospitalizations and post-hospitalization costs. FN risk
and mortality, risk of chemotherapy relative dose intensity (RDI)
<85%, hazard ratio for mortality with RDI <85%, and risk
reduction with pegﬁlgrastim were based on a comprehensive lit-
erature review. Breast cancer mortality by stage and age-speciﬁc
mortality from other causes were obtained from Surveillance
Epidemiology and End Results and National Vital Statistics
Reports. Result robustness was tested using multi-way sensitiv-
ity analyses. RESULTS: For women with stage II breast cancer
receiving chemotherapy with FN risk of 17%, the incremental
cost-effectiveness ratio (ICER) was $41 K per FN episode
avoided. Adding survival beneﬁt due to avoiding FN mortality
yielded an ICER of $72 K/LYG. Adding all proven and hypoth-
esized beneﬁts yielded an ICER of $54 K/LYG. Factors that were
most inﬂuential for the base case ICER included (in order of
inﬂuence) study time horizon, FN case-fatality, baseline FN risk,
FN relative risk reduction, and cost of pegﬁlgrastim. CON-
CLUSION: The value of pegﬁlgrastim primary prophylaxis in
early-stage breast cancer is favorable compared with other oncol-
ogy therapies.
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OBJECTIVES: To assess the cost-effectiveness of breast cancer
risk assessment in primary care, with chemoprevention with
tamoxifen offered to high-risk women. METHODS: A Markov
model was developed to simulate the incidence, health conse-
quences, and costs of invasive breast cancer (IBC) and other clin-
ical events associated with a 5-year course of tamoxifen. Cohorts
at ages 50, 55, and 60 were stratiﬁed by 5-year cancer risk based
on the Gail model. Treatment criteria were deﬁned according to
alternative risk thresholds of 1.67% to 6%. Acceptance of (70%)
and compliance with (68%) chemoprevention were assumed to
be imperfect. Women receiving tamoxifen were assumed to be at
decreased risk for IBC and vertebral fracture, and increased risk
for endometrial cancer, stroke, and venous thromboembolic
events. Breast cancer incidence and survival were derived from
SEER. Other model parameters, including costs and utilities,
were estimated from published literature and clinical trial data.
We discounted costs (2006 US dollars) and quality-adjusted life
years (QALYs) at 3%/year. RESULTS: For 50-year-old women,
risk assessment and chemoprevention based on a 5-year cancer
risk of 4% or greater results in an incremental cost-effectiveness
ratio (ICER) of $49,900 compared to no risk assessment.
Expanding the criterion for chemoprevention to 3%, 2%, and
1.67% leads to incremental cost-effectiveness ratios of $54,400,
$106,000, and $163,000 per QALY, respectively. Thresholds
higher than 4% were weakly dominated. At age 60, ICERs
ranged from $35,300 to $1.3 million per QALY as the treatment
threshold was lowered from 6% to 1.67%. At age 65, thresh-
olds below 5% were dominated. CONCLUSION: Risk assess-
ment and chemoprevention is cost-effective at a $100 K/QALY
threshold at ages 50–65, but more selective criteria for chemo-
prevention at older ages is required to achieve any given cost-
effective criterion.
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OBJECTIVES: In HR positive ABC, HT may be considered stan-
dard treatment before institution of chemotherapy. However, HT
is sometimes substituted by CT early in the disease course, for
example after failure of ﬁrst-line HT. A common treatment
sequence in Brazil is anastrozole followed by successive lines of
docetaxel, capecitabine and gemcitabine. We evaluated the CE
of this treatment sequence (CT sequence) compared to several
other sequences (HT/CT sequences) in which anastrozole and
fulvestrant are used in ﬁrst and second lines, respectively, and
then followed by exemestane and megestrol or megestrol 
and capecitabine or exemestane and capecitabine or megestrol
and exemestane or exemestane and docetaxel, each pair intro-
duced as third and fourth lines, respectively. METHODS: A
Markov model describing the clinical history of HR positive,
ABC, projected improvements in terms of quality-adjusted life
months (QALM), costs, and CE of CT compared to HT/CT. The
time horizon is four treatment lines or the time to patient’s death,
whichever occurred ﬁrst. The simulations were with 10,000
patients for each treatment sequence studied. The reference
patient is a post-menopausal woman with HR positive ABC,
with previous deﬁnitive surgery and adjuvant HT with tamox-
ifen. The disease-progression probabilities for the different treat-
ment drugs/lines and, the quality of life for each health state were
based on the medical literature. Local management and costs of
each health state was based on a Delphi panel, according to the
private health care perspective. Outcomes were discounted at
3% annually. RESULTS: The CE of CT sequence in relation to
HT/CT sequences ranged from R$ 15,000 to R$ 552,000 per
QALM gained. CONCLUSION: As WHO-recommended cost-
utility threshold for Brazil is R$ 2435.75 per QALM gained, CT
is not cost effective in relation to treatment sequences contain-
ing successive lines of HT with fulvestrant in the second line and
introducing chemotherapy in later lines.
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OBJECTIVES: This study is an economic evaluation of currently
recommended colorectal cancer (CRC) screening procedures,
and strategies that incorporate chemopreventive options such as
aspirin or a cycooxygenase-2 inhibitor. METHODS: A decision
analysis model was constructed to compare alternative CRC
screening strategies. A Markov model was employed to simulate
the natural history of CRC. Markov states included Well, Well
with Polyp History, Well with CRC History, CRC-Local, CRC-
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Regional, CRC-Distant, and Dead. Quality adjusted life years
were used as the primary outcome measure. The base case analy-
sis represents the overall cost and effectiveness associated with
each screening strategy. Incremental cost-effectiveness ratios
(ICERs) were calculated for each screening strategy. One-way
sensitivity analyses were performed to assess the factors that
have the greatest effect on the cost-effectiveness of screening.
RESULTS: The most cost-effective screening strategy was Fecal
Occult Blood Test (FOBT); followed by FOBT plus aspirin,
colonoscopy, and colonoscopy plus aspirin. The ICER of FOBT
was $13,014.85 compared to natural history or no intervention.
The model was sensitive to the costs of FOBT, colonoscopy, and
aspirin. The screening strategies were sensitive to the cost of
aspirin, FOBT, and colonoscopy. CONCLUSION: Results from
the analysis showed that the most cost-effective screening strat-
egy was the use of FOBT yearly. In terms of only cost, FOBT
was the least expensive screening strategy whereas the most
expensive was colonoscopy plus COX-2 inhibitor. The results
from the study suggest that FOBT and colonoscopy, as well as
these strategies plus aspirin, are the more cost-effective of all the
screening strategies employed. FOBT plus aspirin and col-
onoscopy have similar cost-effectiveness with colonoscopy
having an ICER of only $35.43.
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OBJECTIVES: To compare cost effectiveness of docetaxel
chemotherapy with other adjuvant treatment regimens in early
and locally advanced breast cancer. METHODS: Cost-effective-
ness Markov model from payer perspective (health insurance and
patient), using costs information from published sources and the
patient lifetime horizon. RESULTS: Two comparisons, TAC
(docetaxel/doxorubicin/cyclophosphamide—75/50/500 mg/m2,
6 cycles) vs FAC (ﬂuorouracil/doxorubicin/cyclophophamide—
500/50/500 mg/m2, 6 cycles) and FEC + T (ﬂuorouracil/
epirubicin/cyclophosphamide—500/100/500 mg/m2, 3 cycles +
docetaxel 100 mg/m2, 3 cycles) vs FEC (ﬂuorouracil/epiru-
bicin/cyclophosphamide—500/100/500 mg/m2, 6 cycles), were
performed. One randomized clinical trial was included for each
comparison. Average costs of the treatment of early or locally
advanced breast cancer (including adjuvant chemotherapy, addi-
tional treatment—tamoxifen/radiotherapy, treatment of adverse
events and disease recurrence) and treatment effects were per
patient: TAC 42883 PLN/25,7 LYG vs FAC 8799 PLN/23,6
LYG; FEC + T 32828 PLN/26,1 LYG vs FEC 13505 PLN/24,7
LYG. ICER for TAC vs FAC comparison was 16558 PLN/LYG.
ICER for FEC + T vs FEC was 13 904 PLN/LYG. CONCLU-
SION: Docetaxel regimens are more effective and more expen-
sive in the treatment of patients with early and locally advanced
breast cancer compared with FAC and FEC chemotherapies,
ICER range 13904-16558 PLN/LYG.
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OBJECTIVES: A recent randomized phase III trial of XP vs. con-
tinuous infusional FP as ﬁrst-line therapy in patients with AGC
met its primary endpoint of non-inferior progression-free sur-
vival (PFS). There was a trend toward superior efﬁcacy seen with
the superiority test for PFS (median 5.6 months for XP vs. 5.0
for FP) and the superior response rates of XP. A pharmacoeco-
nomic model was built to compare costs of the two therapies in
an Italian setting. METHODS: Direct medical costs during the
study were estimated from the Italian hospital perspective. Costs
of the two alternative therapies were estimated based on the trial
results on actual dose and the number of administrations, and
Italian unit costs. Adverse event (AE) proﬁles were used to esti-
mate the cost of treating AEs. An expert panel estimated typical
treatment patterns and costs of treating major AEs like anemia
and febrile neutropenia. RESULTS: AE proﬁles were similar:
associated costs to treat major (grade 3/4) AEs were <€170 per
patient and were lower in the XP arm. Patients in the XP arm
received 5.2 cycles of therapy vs. 4.6 cycles of FP. The substitu-
tion of oral capecitabine for infusional 5-FU reduced the number
of hospital clinic visits by 17.6 (22.8 for FP vs. 5.2 for XP).
Chemotherapy drug costs were estimated to be €1200 greater
with XP, but drug administration costs were €2900 lower, yield-
ing a net cost saving of €1700 per patient. CONCLUSION: Oral
capecitabine in combination with cisplatin would produce sig-
niﬁcant direct medical cost savings from an Italian payer per-
spective. AE costs are similar with the two regimens. Given the
trend to superior efﬁcacy, the projected direct cost savings, and
the convenience of oral treatment, XP would be considered a
dominant (less costly and more effective) regimen for AGC from
the Italian payer perspective.
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OBJECTIVES: To estimate the cost-effectiveness of sunitinib
malate versus palliative/best supportive care (BSC) in the treat-
ment of cytokine-refractory metastatic renal cell carcinoma
(mRCC) in patients failing on IL-2, interferon-alpha or combi-
nation of these. METHODS: A Markov model was developed
and adapted to Argentinean circumstances. Effectiveness results
were taken from a clinical trial and a US Medicare database.
Data was adjusted with general population mortality estimates
from Argentinean life tables. Utilities were collected with the
help of EQ-5D questionnaire in the clinical trial. The main
source of resource use and unit costs was an Oncology Institute
in Argentina. Costs were calculated in 2006 Argentinean pesos
(AR$). Both costs and effectiveness were discounted at a 3%
annual rate. Incremental cost-effectiveness was calculated for
progression-free month (PFM), life-year saved (LYS) and quality
adjusted life years (QALY). Both deterministic and probabilistic
sensitivity analyses were undertaken for effectiveness and cost
variables. RESULTS: Compared to BSC, sunitinib resulted in
2.61 extra PFM, 1.32 LYS and 0.98 QALY; however, at an addi-
tional cost of AR$52,243. The cost of gaining one PFM, LYS
and QALY was AR$9596, AR$39,518 and AR$53,445 respec-
tively. The result was most sensitive to effectiveness parameters.
The incremental cost/QALY was always under the US threshold
of $50,000. CONCLUSION: Though treatment with sunitinib
